Atea Pharmaceuticals (AVIR) Retained Earnings (2019 - 2026)

Atea Pharmaceuticals' Retained Earnings history runs 8 years deep, the most recent figure standing at $801.7 million for Q1 2026.

• On a quarterly basis, Retained Earnings rose 679336.44% year-over-year to $801.7 million in Q1 2026; TTM through Mar 2026 was $801.7 million, a 679336.44% increase from a year earlier, with the FY2025 full-year figure at $797.8 million, up 319.03% from the prior year.
• Retained Earnings was little changed at $801.7 million in Q1 2026 per AVIR's latest filing, from $797.8 million in the prior quarter.
• Across five years, Retained Earnings topped out at $801.7 million in Q1 2026 and bottomed at -$477.7 million in Q3 2025.
• The 5-year median for Retained Earnings is $14.0 million (2022), against an average of $275.5 million.
• Across the five-year window, Retained Earnings sank 74624.49% in 2025 and surged 679336.44% in 2026, its largest moves.
• Year by year, Retained Earnings stood at -$59.9 million in 2022, then soared by 1353.76% to $750.7 million in 2023, then sank by 148.51% to -$364.2 million in 2024, then soared by 319.03% to $797.8 million in 2025, then advanced by 0.5% to $801.7 million in 2026.
• Per Business Quant, the three latest AVIR Retained Earnings figures stand at $801.7 million (Q1 2026), $797.8 million (Q4 2025), and -$477.7 million (Q3 2025).